Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone
Status:
Completed
Trial end date:
2017-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioavailability and the bioequivalence between
two active pharmaceutical ingredient (API) sources of opicapone (OPC) at two different dosage
strengths (25 mg and 50 mg) after a single oral dose administration under fasting conditions
in healthy male and female subjects.